Article

IVI Research Brief Uses Insurance Value to Determine Long-Term Value of Therapies

A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population.

A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population. Insurance value measures the value that medical technologies offer healthy individuals by reducing the physical risks of possible illness, and the concept has been suggested as one of several elements to improve and enhance conventional cost-effecteness analysis.

The brief used IVI's Open-Source Value Platform mofel for rheumatoid arthritis (RA) to explore the application of insurance value because treatent of RA focuses on reducing impacts on quality of life rather than addressing mortality concerns.

Read the full research brief.

Related Videos
Mike Fazio, Navista, Cardinal Health
Dr Kimlin Tam Ashing
Andrew Kuykendall, MD, Moffitt Cancer Center
John Michael O'Brien, PharmD, MPH
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo